Frédérique Schortgen1,2, Emmanuelle Girou3,4, Nicolas Deye5, Laurent Brochard6,7,4. 1. Service de réanimation médicale, AP-HP, Groupe Hospitalier Albert Chenevier-Henri Mondor, Créteil, 94000, France. frederique.schortgen@hmn.aphp.fr. 2. Faculté de Médecine, INSERM, U955, Créteil, 94000, France. frederique.schortgen@hmn.aphp.fr. 3. Unité de Contrôle, Epidémiologie et Prévention de l'Infection, AP-HP, Groupe Hospitalier Albert Chenevier-Henri Mondor, Créteil, 94000, France. 4. Faculté de Médecine, Université Paris 12, Créteil, 94000, France. 5. Réanimation Médicale et Toxicologique, APHP, Hôpital Lariboisière-Fernand Widal, Paris, France. 6. Service de réanimation médicale, AP-HP, Groupe Hospitalier Albert Chenevier-Henri Mondor, Créteil, 94000, France. 7. Faculté de Médecine, INSERM, U955, Créteil, 94000, France.
Abstract
OBJECTIVE: In patients with shock, late-onset acute respiratory distress syndrome (ARDS) carries poor prognosis. Hypooncotic fluids may improve kidney function preservation, whereas hyperoncotic fluids may in theory decrease the risk of late-onset ARDS. Our objective was to determine whether predominant or exclusive use of crystalloids and/or hypooncotic colloids for shock resuscitation influenced the risk of late-onset ARDS. PARTICIPANT AND SETTINGS: International prospective cohort of consecutive adults who were free of ARDS on admission and who received fluid resuscitation for shock in 115 intensive care units (ICUs) during a 4-week period. MEASUREMENTS AND RESULTS: Severity scores, hemodynamic status, indication for fluids, risk factors for ARDS, plasma expander use, transfusions, and late-onset ARDS were recorded prospectively. Logistic regression models were tested to determine whether predominant or exclusive use of hypooncotic fluids was associated with higher incidence of late-onset ARDS. Of 905 patients, 81 [8.9%; 95% confidence interval (CI) 7.2-11.0] developed ARDS, with no difference between patients given only hypooncotic fluids (10.4%; 95% CI 7.6-13.7) and the other patients (7.7%; 95% CI 5.5-10.5; p = 0.16). Late-onset ARDS was significantly associated with sepsis [odds ratio (OR) 1.90; 95% CI 1.06-3.40], worse chest X-ray score at fluid initiation (1.55; 95% CI 1.27-1.91), positive fluid balance (1.06 per l; 95% CI 1.02-1.09), and greater transfusion volume (1.14 per l; 95% CI 1.01-1.29). The proportion of hypooncotic fluids in the plasma expander regimen was not associated with late-onset ARDS (1.01 per %; 95% CI 0.99-1.01). CONCLUSIONS: Based on this observational study, there is no evidence that in patients with shock the use of hypooncotic fluids increases the risk of late-onset ARDS. This finding needs to be confirmed.
OBJECTIVE: In patients with shock, late-onset acute respiratory distress syndrome (ARDS) carries poor prognosis. Hypooncotic fluids may improve kidney function preservation, whereas hyperoncotic fluids may in theory decrease the risk of late-onset ARDS. Our objective was to determine whether predominant or exclusive use of crystalloids and/or hypooncotic colloids for shock resuscitation influenced the risk of late-onset ARDS. PARTICIPANT AND SETTINGS: International prospective cohort of consecutive adults who were free of ARDS on admission and who received fluid resuscitation for shock in 115 intensive care units (ICUs) during a 4-week period. MEASUREMENTS AND RESULTS: Severity scores, hemodynamic status, indication for fluids, risk factors for ARDS, plasma expander use, transfusions, and late-onset ARDS were recorded prospectively. Logistic regression models were tested to determine whether predominant or exclusive use of hypooncotic fluids was associated with higher incidence of late-onset ARDS. Of 905 patients, 81 [8.9%; 95% confidence interval (CI) 7.2-11.0] developed ARDS, with no difference between patients given only hypooncotic fluids (10.4%; 95% CI 7.6-13.7) and the other patients (7.7%; 95% CI 5.5-10.5; p = 0.16). Late-onset ARDS was significantly associated with sepsis [odds ratio (OR) 1.90; 95% CI 1.06-3.40], worse chest X-ray score at fluid initiation (1.55; 95% CI 1.27-1.91), positive fluid balance (1.06 per l; 95% CI 1.02-1.09), and greater transfusion volume (1.14 per l; 95% CI 1.01-1.29). The proportion of hypooncotic fluids in the plasma expander regimen was not associated with late-onset ARDS (1.01 per %; 95% CI 0.99-1.01). CONCLUSIONS: Based on this observational study, there is no evidence that in patients with shock the use of hypooncotic fluids increases the risk of late-onset ARDS. This finding needs to be confirmed.
Authors: Herbert P Wiedemann; Arthur P Wheeler; Gordon R Bernard; B Taylor Thompson; Douglas Hayden; Ben deBoisblanc; Alfred F Connors; R Duncan Hite; Andrea L Harabin Journal: N Engl J Med Date: 2006-05-21 Impact factor: 91.245
Authors: Yasser Sakr; Jean-Louis Vincent; Konrad Reinhart; Johan Groeneveld; Argyris Michalopoulos; Charles L Sprung; Antonio Artigas; V Marco Ranieri Journal: Chest Date: 2005-11 Impact factor: 9.410
Authors: Andrés Esteban; Antonio Anzueto; Fernando Frutos; Inmaculada Alía; Laurent Brochard; Thomas E Stewart; Salvador Benito; Scott K Epstein; Carlos Apezteguía; Peter Nightingale; Alejandro C Arroliga; Martin J Tobin Journal: JAMA Date: 2002-01-16 Impact factor: 56.272
Authors: Ognjen Gajic; Fernando Frutos-Vivar; André Esteban; Rolf D Hubmayr; Antonio Anzueto Journal: Intensive Care Med Date: 2005-04-26 Impact factor: 17.440
Authors: Kinga A Powers; Andras Kapus; Rachel G Khadaroo; Ruijuan He; John C Marshall; Thomas F Lindsay; Ori D Rotstein Journal: Crit Care Med Date: 2003-09 Impact factor: 7.598
Authors: R S Simmons; G G Berdine; J J Seidenfeld; T J Prihoda; G D Harris; J D Smith; T J Gilbert; E Mota; W G Johanson Journal: Am Rev Respir Dis Date: 1987-04
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2011-01-12 Impact factor: 17.440
Authors: Chiedozie I Udeh; Jing You; Matthew R Wanek; Jarrod Dalton; Belinda L Udeh; Sevag Demirjian; Nadeem Rahman; J Steven Hata Journal: Perioper Med (Lond) Date: 2018-12-14